<DOC>
	<DOCNO>NCT00320463</DOCNO>
	<brief_summary>In study , infant randomly allocate three group : - one group subject receive DTPa-HBV-IPV/Hib vaccine ( new formulation ) - second group subject receive DTPa-HBV-IPV/Hib vaccine ( current formulation ) - third group subject receive DTPa-HBV-IPV vaccine The study double-blind two group receive DTPa-HBV-IPV/Hib vaccine ( new current formulation ) . The study single-blind group receive DTPa-HBV-IPV vaccine .</brief_summary>
	<brief_title>Compare Immunogenicity &amp; Safety 2 Formulations GSK Biologicals ' DTPa-HBV-IPV/Hib Vaccine Given Healthy Infants</brief_title>
	<detailed_description>A study compare immunogenicity &amp; safety 2 formulation GlaxoSmithKline ( GSK ) Biologicals ' DTPa-HBV-IPV/Hib vaccine give healthy infant 3,4 &amp; 5 month age . The immunogenicity &amp; safety DTPa-HBV-IPV vaccine also evaluate 3rd group subject Subjects group receive DTPa-HBV-IPV/Hib vaccine ( current formulation ) control group group receive DTPa-HBV-IPV/Hib vaccine ( new formulation )</detailed_description>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>`` Inclusion criterion : A healthy male female infant , include , 11 17 week age time first vaccination . Infant bear know hepatitis B surface antigen ( HBsAg ) seronegative mother ( document laboratory result HBsAg assay maternal blood sample available ) . Born normal gestation period ( 36 42 week ) . Written inform consent obtain parent guardian subject . Exclusion criterion : Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Any chronic drug therapy continue study period . Planned administration/ administration vaccine foreseen study protocol period start 30 day dose study vaccine end 30 day last vaccine dose . Previous vaccination diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B and/or Haemophilus influenzae disease . Known history exposure diphtheria , tetanus , pertussis , poliomyelitis , hepatitis B and/or Haemophilus influenzae disease since birth . History allergic disease reaction likely exacerbate component vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>11 Weeks</minimum_age>
	<maximum_age>17 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>